Imunon to discuss Q1 2026 financials and Phase 3 trial progress for ovarian cancer immunotherapy on May 12.

Imunon, Inc. will hold a conference call on May 12, 2026, to report its first quarter financial results and update investors on the clinical development of IMNN-001, its DNA-based immunotherapy for advanced ovarian cancer. The company is advancing Phase 3 trials of IMNN-001, which aims to boost cancer-fighting molecules at tumor sites. This update follows successful Phase 2 trials showing improved survival rates, positioning IMNN-001 as a promising treatment option. Investors can join the call via phone or webcast to learn more about the company’s progress and future plans.